Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-04-18
1998-10-20
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514299, 514342, 514367, 514370, A61K 31425
Patent
active
058246940
ABSTRACT:
A new medical use for certain thiazolidine derivatives is disclosed. Specifically, treatment of hyperproliferative epithelial cell conditions, such as psoriasis, by administration of thiazolidinediones or 5'-aryl substituted thiazolidine derivatives is described. Appropriate chemical structures, synthetic reactions, formulations, routes of administration and dosages are included.
REFERENCES:
patent: 4444779 (1984-04-01), Kawamatsu
patent: 4461902 (1984-07-01), Kawamatsu
patent: 4486594 (1984-12-01), Kawamatsu
patent: 4572912 (1986-02-01), Yoshioka
patent: 4582839 (1986-04-01), Meguro
patent: 4703052 (1987-10-01), Eggler
patent: 4725610 (1988-02-01), Meguro
patent: 4775687 (1988-10-01), Meguro
patent: 4812570 (1989-03-01), Meguro
patent: 5002953 (1991-03-01), Hindley
patent: 5023085 (1991-06-01), Francoeur et al.
patent: 5053420 (1991-10-01), Pershadsingh
patent: 5143928 (1992-09-01), Cetenko
patent: 5252735 (1993-10-01), Morris
Barry, Brian W., Dermatological Formulations, 1983: pp. 181-186.
Colca et al., Ciglitazone, A Hypoglycemic Agent: Early Effects on the Pancreatic Islets of Ob/Ob Mice, Metabolism, vol. 37, No. 3 (Mar.), 1988: pp. 276-280.
Chang et al., Ciglitazone, a New Hypoglycemic Agent, Diabetes , vol. 32 (Sep.), 1983: pp. 830-838.
Wyrick et al., Effects of Molecular Modification on Hypocholesteremic Activity of 1,3-Bis (substituted phenoxy)--2-propanones and Related Derivatives, Journal of Medicinal Chemistry , vol. 21, 1978: pp. 386-390.
Zask et al., Synthesis and Antihyperglycemic Activity of Novel 5-(Naphthalenylsulfony)-2, 4-thiazolidinediones, J. Med. Chem , vol. 33, 1990: pp. 1418-1423.
Boyce et al., Calcium-Regulated Differentiation of Normal Human Epidermal Keratinocytes in Chemically Defined Clonal Culture and Serum-Free Serial Culture, The Journal of Investigative Dermatology , vol. 81, 1983: pp. 33s-40s.
Kitano et al., Suppression of Proliteration of Human Epidermal Keratinocytes by 1, 25-dihydroxyvitamin D.sub.3, European Journal of Clinical Investigation , vol. 21, 1991: pp. 53-58.
West et al., Simple Assays of Retiniod Activity As Potential Screens For Compounds That May Be Useful In Treatment Of Psoriasis, The Society for Investigative Dermatology, Inc., vol. 100, 1992: pp. 95-100.
Menter et al., Psoriasis in Practice, The Lancet , vol. 338, (Jul. 27) 1991: pp. 231-234.
Barker, The Pathophysiology of Psoriasis, The Lancet , vol. 338, (Jul. 27) 1991: pp. 227-230.
Kurtz Theodore W.
Pershadsingh Harrihar A.
Bethesda Pharmaceuticals, Inc.
Killos Paul J.
LandOfFree
Thiazolidine derivatives for the treatment of psoriasis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolidine derivatives for the treatment of psoriasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolidine derivatives for the treatment of psoriasis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244737